Screener
Aura Biosciences, Inc. AURA Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Aura Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Aura Biosciences, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-216808
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $84,793 | $59,515 |
| Marketable securities | 29,940 | 84,726 |
| Prepaid expenses and other current assets | 3,771 | 5,498 |
| Total current assets | 118,504 | 149,739 |
| Restricted cash and deposits | 768 | 768 |
| Right-of-use assets - operating lease | 15,416 | 15,828 |
Item 1. Financial Statements.
FAQ
- What is Aura Biosciences, Inc.'s cash & equivalents?
- Aura Biosciences, Inc. (AURA) reported cash & equivalents of $84.79M in Q1 2026.
- How has Aura Biosciences, Inc.'s cash & equivalents changed year-over-year?
- Aura Biosciences, Inc.'s cash & equivalents increased by 121.8% year-over-year, from $38.23M to $84.79M.
- What is the long-term trend for Aura Biosciences, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Aura Biosciences, Inc.'s cash & equivalents has grown at a 27.9% compound annual growth rate (CAGR), from $17.39M to $59.52M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Aura Biosciences, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude